JAMA vs European Heart Journal: Which Journal Should You Choose?

JAMA asks whether a cardiovascular paper matters to general medicine. European Heart Journal asks whether it's one of the best cardiovascular papers in the field.

That's why these journals can both be elite and still be poor substitutes for one another.

If the paper depends on cardiology-native framing, imaging nuance, ESC relevance, or field-specific endpoint logic to show its force, EHJ usually becomes more natural. If the paper can be understood immediately by a broader physician audience and the practical consequence is obvious beyond cardiology, JAMA becomes realistic.

JAMA wins when the cardiovascular study behaves like a broad clinical paper.

That usually means:

• a trial or cohort result with consequences outside cardiology
• a prevention, health-services, or comparative-effectiveness paper with broad physician relevance
• a cardiovascular topic whose policy or care-delivery significance is obvious
• a manuscript that gets sharper when framed for general medical readers

JAMA's editorial guidance in the repo are explicit that the journal rewards broad clinical importance, not just field prestige.

EHJ wins when the paper is elite cardiology and the field is the right audience.

That includes:

• major cardiovascular registries
• ESC-relevant clinical studies
• prevention and risk-stratification work
• imaging papers with direct cardiovascular consequence
• top-tier heart-failure, interventional, or outcomes papers that remain specialty-defined

This is exactly what EHJ guides and's editorial guidance suggest. A paper can be extremely strong and still belong first in EHJ because its strongest interpretation depends on a cardiovascular reader.

JAMA's editorial guidance emphasize comparative effectiveness, health policy, systematic reviews, and broad clinical utility. That can make JAMA a better fit than EHJ for some cardiovascular population-health or care-delivery studies that cross specialties.

The current Oxford Academic instructions show a detailed specialist workflow: Clinical Research Articles up to 5,000 words, structured text abstracts, structured graphical abstracts, and ESC / OUP submission mechanics. That's the architecture of a field-leading cardiology journal, not a general-medical venue.

The official EHJ instructions state that manuscripts may be screened for integrity issues such as papermill activity, and that AI use should be disclosed. That's another signal that the journal expects a tightly prepared and transparent package.

A paper can be an excellent cardiology manuscript and still feel too specialty-shaped for JAMA. That's one of the most common overtargeting mistakes with flagship general journals.

• the paper has visible importance beyond cardiology
• the result affects broad clinical care, health policy, or comparative effectiveness
• non-cardiologists will understand why it matters immediately
• the manuscript becomes stronger when stripped down to the most general clinical consequence

That's the narrower lane.

• the paper is top-tier cardiovascular research
• cardiologists are the main audience
• ESC-facing relevance, cardiovascular registries, imaging, prevention, or field-specific interpretation are central
• the paper would lose force if you flattened the cardiology logic for a general-medical audience

That's often the more realistic and more powerful first move.

This is a sensible cascade.

If JAMA rejects the manuscript because it's too specialty-defined, European Heart Journal can be a strong next move.

That works especially well when:

• the study is still one of the stronger papers in cardiovascular medicine
• the methods are solid
• the result matters deeply inside cardiology
• the paper is better served by specialist readers than by broader general-medical framing

It works less well when the paper's real problem is methodological weakness or a modest clinical consequence. JAMA rejection for fit can still lead to EHJ. JAMA rejection for thinness often won't.

If a manuscript sounds general-medical only because the cover letter and abstract were widened after the fact, editors usually notice quickly.

The journal's editorial patterns for EHJ is clear on this. A single-center paper, an overclaimed observational analysis, or a study without obvious field-level consequence becomes vulnerable fast.

These are often more natural EHJ papers unless they clearly change broad clinical policy or practice beyond cardiology.

Imaging papers with high cardiovascular consequence commonly belong in EHJ because the value depends on field-native interpretation.

This category can go either way. If the implications are broad across medicine or public health, JAMA becomes more plausible. If the paper is still primarily a cardiology conversation, EHJ usually wins.

The biggest cardiovascular trials can go to either journal. The deciding question is whether the paper reads like a field-defining cardiology paper or a broad clinical event.

A strong JAMA first page usually makes the broad clinical consequence easy to see. The manuscript shouldn't need much specialty setup before the importance lands.

A strong EHJ first page can carry more cardiovascular-native language, but it still has to show why the study matters to the field quickly. The official EHJ structure requirements, including the structured graphical abstract, reinforce that expectation for clarity and field-facing presentation.

That difference is often visible before submission.

Ask which sentence fits the paper better:

• "this changes what physicians broadly should do or think" points toward JAMA
• "this changes what cardiologists should do or think" points toward European Heart Journal

That isn't simplistic. It's often the most useful distinction.

EHJ can be the better strategic choice when the paper's value depends on a cardiovascular reader appreciating the full context. That includes:

• disease-specific endpoint logic
• guideline-adjacent implications
• imaging interpretation
• registry context
• specialist prevention or risk frameworks

In those cases, forcing the paper toward JAMA can actually weaken the manuscript's most persuasive features.

Send to JAMA first if:

1. the paper has clear importance beyond cardiology
2. a broad physician readership should care immediately
3. the manuscript becomes more powerful, not less, when framed for general medicine

Send to European Heart Journal first if:

1. the paper is one of the strongest cardiovascular papers in its class
2. the field itself is the right audience
3. ESC relevance, registry logic, or cardiovascular-specific interpretation are central
4. the paper loses clarity when generalized too far